IPOs https://www.benzinga.com/views/taxonomy/term/34991 en ARYA Sciences Acquisition Corp II Announces Pricing of $130 Million Initial Public Offering https://www.benzinga.com/pressreleases/20/06/g16186582/arya-sciences-acquisition-corp-ii-announces-pricing-of-130-million-initial-public-offering <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p>NEW YORK, NY, June 04, 2020 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp II (the "Company"), a special purpose acquisition company formed for the purpose of entering into a combination with one or more businesses or entities, today announced the pricing of its initial public offering of 13,000,000 units at a price of $10.00 per unit. The units will be listed on The Nasdaq Capital Market ("Nasdaq") and trade under the ticker symbol "ARYBU" beginning on June 5, 2020. Each unit consists of one Class A ordinary share of the Company and one-third of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share of the Company at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols "ARYB" and "ARYBW," respectively.</p> <p>While the Company may pursue an initial business combination target in any business or industry, it intends to focus on the healthcare industry in the United States ...</p><p><a href=https://www.benzinga.com/pressreleases/20/06/g16186582/arya-sciences-acquisition-corp-ii-announces-pricing-of-130-million-initial-public-offering alt=ARYA Sciences Acquisition Corp II Announces Pricing of $130 Million Initial Public Offering>Full story available on Benzinga.com</a></p> ARYB ARYBU ARYBW News IPOs Press Releases Fri, 05 Jun 2020 03:54:19 +0000 Globe Newswire 16186582 at https://www.benzinga.com Applied Molecular Transport Announces Pricing of Initial Public Offering https://www.benzinga.com/pressreleases/20/06/g16186366/applied-molecular-transport-announces-pricing-of-initial-public-offering <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="justify">SOUTH SAN FRANCISCO, Calif., June 04, 2020 (GLOBE NEWSWIRE) -- Applied Molecular Transport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMTI#NASDAQ" rel="nofollow">AMTI</a>), a clinical-stage biopharmaceutical company, today announced the pricing of its initial public offering of 11,000,000 shares of common stock at a public offering price of $14.00 per share. All of the shares of common stock are being offered by AMT. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by AMT, are expected to be $154.0 million, excluding any exercise of the underwriters&#039; option to purchase additional shares. The shares are expected to begin trading on the Nasdaq Global Select Market on June 5, 2020, under the ticker symbol "AMTI." The offering is expected to close on June 9, 2020, subject to the satisfaction of customary closing conditions. In addition, AMT has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.<br /></p> <p align="justify">BofA Securities, Jefferies and SVB Leerink are acting as joint book-running managers for this offering.</p> <p align="justify">Registration statements relating to the shares being sold in this offering have been filed ...</p><p><a href=https://www.benzinga.com/pressreleases/20/06/g16186366/applied-molecular-transport-announces-pricing-of-initial-public-offering alt=Applied Molecular Transport Announces Pricing of Initial Public Offering>Full story available on Benzinga.com</a></p> AMTI News IPOs Press Releases Fri, 05 Jun 2020 02:40:36 +0000 Globe Newswire 16186366 at https://www.benzinga.com ZoomInfo IPO: What You Need To Know https://www.benzinga.com/news/20/06/16160567/zoominfo-ipo-what-you-need-to-know <p>If you&rsquo;re looking for fresh exposure to artificial intelligence and machine learning, this B2B database&nbsp;wants your capital.</p> <h3><strong>The IPO</strong></h3> <p><strong><a href="https://www.zoominfo.com/">ZoomInfo Technologies Inc.</a></strong>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zi#NASDAQ">ZI</a>) will issue 44.5 million shares on the Nasdaq under ticker &quot;ZI,&quot; according to the firm&rsquo;s <a href="https://www.sec.gov/Archives/edgar/data/1794515/000162828020008791/zoominfos-1a4.htm">S-1 filing</a>. Priced between $16 and $18, the offering represents 98.1% of outstanding shares and is expected to bring in about $921.2 million.</p> <p>On Thursday morning, the IPO was priced at $21 per share.</p> <p>The lead underwriters include JPMorgan and Morgan ...</p><p><a href=https://www.benzinga.com/news/20/06/16160567/zoominfo-ipo-what-you-need-to-know alt=ZoomInfo IPO: What You Need To Know>Full story available on Benzinga.com</a></p> News ZI ZoomInfo Technologies Previews IPOs Trading Ideas ZI News Previews IPOs Trading Ideas Benzinga Thu, 04 Jun 2020 13:19:10 +0000 Elizabeth Balboa 16160567 at https://www.benzinga.com ZoomInfo Raises $935M In Its IPO, Beating Market Expectations https://www.benzinga.com/news/20/06/16177120/zoominfo-raises-935m-in-its-ipo-beating-market-expectations <p>ZoomInfo on Wednesday raised $935 million in its initial public offering.</p> <p>The business database provider sold 44.5 million shares priced at $21 each, as earlier <a href="https://www.ft.com/content/7fbee530-ddf1-4db7-885d-76ad33acb4cd">reported</a> by the Financial Times.</p> <p>The public offering, which is the largest so far this year among technology companies, puts ZoomInfo&#39;s valuations ...</p><p><a href=https://www.benzinga.com/news/20/06/16177120/zoominfo-raises-935m-in-its-ipo-beating-market-expectations alt=ZoomInfo Raises $935M In Its IPO, Beating Market Expectations>Full story available on Benzinga.com</a></p> Covid-19 News The Financial Times WMG IPOs Media WMG News IPOs Media Benzinga Thu, 04 Jun 2020 09:03:21 +0000 Neer Varshney 16177120 at https://www.benzinga.com New Leaf Ventures Closes Second And Final Tranche Of IPO https://www.benzinga.com/markets/cannabis/20/06/16173172/new-leaf-ventures-closes-second-and-final-tranche-of-ipo <p>Health care investment firm <strong>New Leaf Ventures Inc. </strong>(CSE: NLV) announced Wednesday the closing of a second tranche of its initial public offering.</p> <p>The second tranche of 2,990,400 units which went out at a price of 25 cents&nbsp;per unit gathered aggregate gross proceeds of approximately $747,600.</p> <p>Each unit consists of one common share and one half common share purchase warrant.</p> <p>In early May, the company had announced the completion of an IPO of 4,768,871 units for aggregate gross proceeds ...</p><p><a href=https://www.benzinga.com/markets/cannabis/20/06/16173172/new-leaf-ventures-closes-second-and-final-tranche-of-ipo alt=New Leaf Ventures Closes Second And Final Tranche Of IPO>Full story available on Benzinga.com</a></p> Cannabis Mike Stier New Leaf Ventures News Financing IPOs Markets News Cannabis Financing IPOs Markets Benzinga Wed, 03 Jun 2020 22:05:16 +0000 Natan Ponieman 16173172 at https://www.benzinga.com Warner Music CEO On IPO: Music Is The 'Only Global Language' https://www.benzinga.com/news/20/06/16172119/warner-music-ceo-on-ipo-music-is-the-only-global-language <p>Warner Music Group Corp. priced its 77-million-share IPO at $25 per share, and the stock opened higher Wednesday at $27.&nbsp;</p> <p>As a company returning to the public markets, investors have plenty to ask about Warner, and CEO Stephen Cooper was a guest on <a href="https://www.cnbc.com/video/2020/06/03/warner-music-ceo-stephen-cooper-on-decision-to-re-enter-public-markets.html">CNBC&#39;s &quot;Squawk on the Street&quot;</a> to address some of the questions.&nbsp;</p> <h3>Warner&#39;s Margin Profile</h3> <p>Some investors are worried Warner Music&#39;s margins didn&#39;t improve as much as they should amid a shift from physical to digital music, CNBC&#39;s David Faber said. The CEO answered said the &quot;spread&quot; in margins between physical and digital is around 15 points.</p> <p>The company prioritized much of its free cash flow ...</p><p><a href=https://www.benzinga.com/news/20/06/16172119/warner-music-ceo-on-ipo-music-is-the-only-global-language alt=Warner Music CEO On IPO: Music Is The &#039;Only Global Language&#039;>Full story available on Benzinga.com</a></p> AAPL CNBC Music News SPOT Squawk on the Street Stephen Cooper Streaming music WMG Management IPOs Media AAPL US0378331005 WMG SPOT News Management IPOs Media Benzinga Wed, 03 Jun 2020 19:47:41 +0000 Jayson Derrick 16172119 at https://www.benzinga.com Chinese EV Maker Xpeng Motors Seeks $500M US IPO: Report https://www.benzinga.com/news/20/06/16168930/chinese-ev-maker-xpeng-motors-seeks-500m-us-ipo-report <p>Electric vehicle pioneer <strong>Tesla Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) might be getting more tough competition from the Chinese EV market.</p> <p><strong>Nio Inc &ndash; ADR </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nio#NYSE">NIO</a>) hit the U.S. markets back in September of 2018, and now <strong>Xpeng Motors</strong> is planning a U.S. listing, the <a href="http://www.scmp.com/tech/start-ups/article/3087121/chinas-tesla-challenger-xpeng-said-be-preparing-us-listing-countrys">South China Morning Post reported</a>.</p> <h3><strong>What Is Xpeng Motors?</strong></h3> <p>Xpeng, ...</p><p><a href=https://www.benzinga.com/news/20/06/16168930/chinese-ev-maker-xpeng-motors-seeks-500m-us-ipo-report alt=Chinese EV Maker Xpeng Motors Seeks $500M US IPO: Report>Full story available on Benzinga.com</a></p> BABA electric vehicles News NIO TSLA Xiaomi Xpeng Motors IPOs Media TSLA US88160R1014 BABA NIO News IPOs Media Benzinga Wed, 03 Jun 2020 17:58:56 +0000 Shanthi Rexaline 16168930 at https://www.benzinga.com Warner Music IPO: What You Need To Know https://www.benzinga.com/news/20/06/16160987/warner-music-ipo-what-you-need-to-know <p>Superfans of Lizzo, Ed Sheeran and Cardi B can now cash in on their idols&rsquo; latest hits by investing in this newly public company.</p> <h3><strong>The IPO</strong></h3> <p><a href="https://www.wmg.com/"><strong>Warner Music Group Corp.</strong></a> will issue 70 million shares on the Nasdaq under ticker WMG, according to the firm&rsquo;s <a href="https://www.sec.gov/Archives/edgar/data/1319161/000119312520155952/d833365ds1a.htm">S-1 filing</a>. Priced between $23 and $26, the offering represents 100%&nbsp;of outstanding shares and is expected to bring in about $2.093 billion.</p> <p>Early Wednesday morning, the company priced its 77-million&nbsp;share IPO ...</p><p><a href=https://www.benzinga.com/news/20/06/16160987/warner-music-ipo-what-you-need-to-know alt=Warner Music IPO: What You Need To Know>Full story available on Benzinga.com</a></p> News warner music group WMG Previews IPOs Trading Ideas WMG News Previews IPOs Trading Ideas Benzinga Wed, 03 Jun 2020 12:10:13 +0000 Elizabeth Balboa 16160987 at https://www.benzinga.com The Daily Biotech Pulse: Regulatory Delay For Novartis' Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study https://www.benzinga.com/general/biotech/20/06/16167710/the-daily-biotech-pulse-regulatory-delay-for-novartis-multiple-sclerosis-drug-fsd-gets-nod-for-co <p>Here&#39;s a roundup of top developments in the biotech space over the last 24 hours.</p> <h3>Scaling The Peaks</h3> <p><em>(Biotech Stocks Hitting 52-week Highs June 2)</em></p> <ul> <li><strong>Agenus Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agen#NASDAQ">AGEN</a>)(announced FDA clearance of its IND for evaluating its allogeneic iNKT therapy as a COVID-19 treatment option)</li> <li><strong>Arena Pharmaceuticals, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arna#NASDAQ">ARNA</a>)(moved on a positive readout for a rival ulcerative colitis drug from <strong> Bristol-Myers Squibb Co </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bmy#NYSE">BMY</a>))</li> <li><strong>argenx SE &ndash; ADR </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/argx#NASDAQ">ARGX</a>)</li> <li><strong>Bio-Rad Laboratories, Inc. Class A Common Stock </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bio#NYSE">BIO</a>)</li> <li><strong>Biohaven Pharmaceutical Holding Co Ltd </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bhvn#NYSE">BHVN</a>)</li> <li><strong>Cardiff Oncology Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crdf#NASDAQ">CRDF</a>)</li> <li><strong>Fortress Biotech </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fbio#NASDAQ">FBIO</a>)</li> <li><strong>Imara Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imra#NASDAQ">IMRA</a>)</li> <li><strong>Kala Pharmaceuticals Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kala#NASDAQ">KALA</a>)</li> <li><strong>ORIC Pharmaceuticals Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/oric#NASDAQ">ORIC</a>)</li> <li><strong>Protara Therapeutics Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tara#NASDAQ">TARA</a>)</li> <li><strong>Qiagen NV </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/qgen#NYSE">QGEN</a>)</li> <li><strong>Regeneron Pharmaceuticals Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/regn#NASDAQ">REGN</a>)</li> <li><strong>Tenax Therapeutics Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tenx#NASDAQ">TENX</a>)(<a href=" https://www.benzinga.com/general/biotech/20/06/16160336/whats-driving-shares-of-nano-cap-pharma-tenax-higher"> announced </a> a positive Phase 3 readout)</li> <li><strong>Trillium Therapeutics Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tril#NASDAQ">TRIL</a>)</li> <li><strong>Turning Point Therapeutics Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tptx#NASDAQ">TPTX</a>)</li> <li><strong>Unity Biotechnology Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ubx#NASDAQ">UBX</a>)</li> <li><strong>Vermillion, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrml#NASDAQ">VRML</a>)</li> <li><strong>Y-mAbs Therapeutics, Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ymab#NASDAQ">YMAB</a>)(announced FDA acceptance of its BLA for Danyelza for the treatment of patients with relapsed/refractory high-risk neuroblastoma)</li> </ul> <h3>Down In The Dumps</h3> <p><em>(Biotech Stocks Hitting 52-week Lows June 2)</em></p> <ul> <li><strong>Exagen Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xgn#NASDAQ">XGN</a>)</li> </ul> <h3>Stocks In Focus</h3> <h3>Novartis Announces 3-Month Extension In Regulatory Review Period For Multiple Sclerosis Drug</h3> <p><strong>Novartis AG </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvs#NYSE">NVS</a>) announced the receipt of a notification from the FDA, extending the review of its sNDA for ofatumumab for patients with relapsing multiple sclerosis. The company said the regulatory action would ...</p><p><a href=https://www.benzinga.com/general/biotech/20/06/16167710/the-daily-biotech-pulse-regulatory-delay-for-novartis-multiple-sclerosis-drug-fsd-gets-nod-for-co alt=The Daily Biotech Pulse: Regulatory Delay For Novartis&#039; Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study>Full story available on Benzinga.com</a></p> AGEN ANIK ANPC ARGX ARNA BHVN BIO Biotech BMY CRDF EVFM FBIO HUGE IBB IMRA KALA KNSA LLY News NVAX NVS ORIC Penny Stocks QGEN REGN REPL TARA TENX TPTX TRIL UBX VRML XBI XGN YMAB Health Care Offerings FDA Management IPOs Top Stories Pre-Market Outlook Trading Ideas General XBI US78464A8707 AGEN US00847G7051 ANIK US0352551081 ARNA US0400471027 IBB US4642875565 NVAX US6700021040 QGEN NL0000240000 REGN US75886F1075 TPTX BIO US0905722072 BMY US1101221083 LLY US5324571083 NVS US66987V1098 VRML US92407M2061 REPL TRIL TENX FBIO BHVN ARGX KALA EVFM UBX KNSA HUGE YMAB XGN ANPC TARA IMRA ORIC CRDF News Biotech Penny Stocks Health Care Offerings FDA Management IPOs Top Stories Pre-Market Outlook Trading Ideas General Benzinga Wed, 03 Jun 2020 11:39:19 +0000 Shanthi Rexaline 16167710 at https://www.benzinga.com Warner Music Group Corp. Announces Pricing of Initial Public Offering https://www.benzinga.com/pressreleases/20/06/g16167189/warner-music-group-corp-announces-pricing-of-initial-public-offering <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="left">NEW YORK, June 03, 2020 (GLOBE NEWSWIRE) -- Warner Music Group Corp. (the "Company") announced today the pricing of its initial public offering ("IPO") of 77,000,000 shares of its Class A common stock at a public offering price of $25.00 per share.  The size of the IPO was increased from the previously announced 70,000,000 shares of Class A common stock.  The offering consists entirely of secondary shares to be sold by Access Industries, LLC and certain related selling stockholders.  The Company will not receive any proceeds from the offering.  The shares of Class A common stock are expected to begin trading on The Nasdaq Stock Market on June 3, 2020 under the ticker symbol "WMG".  The underwriters will have a 30-day option to purchase up to an additional 11,550,000 shares of Class A common stock from the selling stockholders.<br /></p> <p>Morgan Stanley &amp; Co. LLC, Credit Suisse Securities (USA) LLC and Goldman Sachs &amp; Co. LLC are acting as joint bookrunning managers and as representatives of the underwriters for the offering.  BofA Securities, Inc., Citigroup Global Markets Inc. and J.P. Morgan Securities LLC are also acting as joint bookrunning managers.  ...</p><p><a href=https://www.benzinga.com/pressreleases/20/06/g16167189/warner-music-group-corp-announces-pricing-of-initial-public-offering alt=Warner Music Group Corp. Announces Pricing of Initial Public Offering>Full story available on Benzinga.com</a></p> News WMG IPOs Press Releases Wed, 03 Jun 2020 10:20:43 +0000 Globe Newswire 16167189 at https://www.benzinga.com Warner Music Set To Go Public Today, In Anticipated Largest US IPO Of The Year https://www.benzinga.com/news/20/06/16166589/warner-music-set-to-go-public-today-in-anticipated-largest-us-ipo-of-the-year <p>Warner Music is set to list at the Nasdaq Stock Market on Wednesday.</p> <h3>Warner Music Could Kickstart A String Of IPOs This Year</h3> <p>The record label giant is expected to price the initial public offering between $23 to $26 per share, and raise between $11.7 billion and $13.3 billion.</p> <p>According to the Wall Street Journal, Warner Music is <a href="https://www.wsj.com/articles/warner-music-and-zoominfo-poised-to-breathe-life-into-ipo-market-11591090200?mod=rsswn">aiming towards</a> the higher end of that range for pricing its IPO, which will be the largest year-till-date in the United States.</p> <p>The IPO sector has been battered by the economic impact of the novel coronavirus (COVID-19) ...</p><p><a href=https://www.benzinga.com/news/20/06/16166589/warner-music-set-to-go-public-today-in-anticipated-largest-us-ipo-of-the-year alt=Warner Music Set To Go Public Today, In Anticipated Largest US IPO Of The Year>Full story available on Benzinga.com</a></p> AAPL AMZN Covid-19 George Floyd GOOG GOOGL News SPOT The Verge The Wall Street Journal Warner Music IPOs Media General AAPL US0378331005 AMZN US0231351067 GOOG US38259P7069 GOOGL US38259P5089 SPOT News IPOs Media General Benzinga Wed, 03 Jun 2020 10:09:31 +0000 Neer Varshney 16166589 at https://www.benzinga.com Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares https://www.benzinga.com/pressreleases/20/06/g16156432/adaptimmune-therapeutics-plc-prices-public-offering-of-american-depositary-shares <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="left">PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 01, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc ("Adaptimmune")(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ" rel="nofollow">ADAP</a>), a leader in cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 20,500,000 of its American Depositary Shares ("ADSs") at a price to the public of $11.00 per ADS. In connection with the offering, Adaptimmune has granted the underwriters a 30-day option to purchase up to an additional 3,075,000 ADSs at the public offering price. The gross offering size for this offering is expected to be $225.5 million, excluding any exercise of the underwriters&#039; option to purchase additional ADSs. All ADSs in this offering are being sold by Adaptimmune with net proceeds to be used to advance the development of Adaptimmune&#039;s immunotherapies into and through clinical trials as well as for other general corporate purposes. This offering is expected to close on or about June 4, 2020, subject to customary closing conditions.<br /></p> <p>Cowen and SVB Leerink are acting as joint book-running managers for the offering and Roth Capital Partners is acting as lead manager for the offering.</p> <p>A shelf registration statement on Form S-3 relating to the public offering of the ADSs described above was declared effective by the Securities and Exchange Commission ("SEC") on September 10, 2019. The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC&#039;s web site at <a href="http://www.sec.gov" title="www.sec.gov" rel="nofollow">www.sec.gov</a>. Copies of the final prospectus supplement and ...</p><p><a href=https://www.benzinga.com/pressreleases/20/06/g16156432/adaptimmune-therapeutics-plc-prices-public-offering-of-american-depositary-shares alt=Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares>Full story available on Benzinga.com</a></p> ADAP News IPOs Press Releases Tue, 02 Jun 2020 01:39:00 +0000 Globe Newswire 16156432 at https://www.benzinga.com Aura provides update on Plans for Initial Public Offering and Listing in Brazil https://www.benzinga.com/pressreleases/20/06/g16155929/aura-provides-update-on-plans-for-initial-public-offering-and-listing-in-brazil <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="justify">ROAD TOWN, British Virgin Islands, June 01, 2020 (GLOBE NEWSWIRE) -- <strong>Aura Minerals Inc. </strong><strong>(TSX:<a class="ticker" href="https://www.benzinga.com/stock/ORA#TSX" rel="nofollow">ORA</a>) </strong>(the &#34;<strong>Company</strong>&#34; or "<strong>Aura</strong>") today announced that the Company is resuming the process commenced in the first quarter of 2020 to explore a possible initial public offering (the "<strong>Offering</strong>") in Brazil and concurrent listing of Brazilian depositary receipts (&#34;<strong>BDRs</strong>&#34;), sponsored level III, to be issued by a depositary institution, each BDR representing one share of the Company ("<strong>Shares</strong>"), pursuant to Brazilian Securities Commission (<em>Comissão de Valores Mobiliários</em>, or the "<strong>CVM</strong>") Instruction No. 332, dated April 4, 2000, as amended. As announced by the Company on March 3, 2020, the Company was previously working towards completing an initial public offering of BDRs in Brazil, which plans the Company subsequently suspended in light of the ongoing COVID-19 pandemic as announced by it on March 24, 2020.<br /></p> <p align="justify">It is expected that the Shares underlying the BDRs would be comprised of a combination of (i) Shares to be issued by the Company and (ii) Shares to be sold by certain selling shareholder(s). The Company has also applied to list the BDRs on B3 S.A. – Brasil, Bolsa, Balcão (the "<strong>B3</strong>").</p> <p align="justify"><strong>No Shares or BDRs would be offered in Canada as part of the Offering.</strong></p> <p align="justify">Completion of the Offering is subject to, among other factors, the Company obtaining all necessary approvals, including approvals required under applicable corporate law, registration of the Company as a foreign issuer in Brazil by the CVM, registration of the Offering by the CVM (if applicable) and approval of the listing of the BDRs and Shares by the B3 and the Toronto Stock Exchange, respectively; political and ...</p><p><a href=https://www.benzinga.com/pressreleases/20/06/g16155929/aura-provides-update-on-plans-for-initial-public-offering-and-listing-in-brazil alt=Aura provides update on Plans for Initial Public Offering and Listing in Brazil>Full story available on Benzinga.com</a></p> News TSX:ORA IPOs Press Releases Mon, 01 Jun 2020 23:00:10 +0000 Globe Newswire 16155929 at https://www.benzinga.com The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight https://www.benzinga.com/general/biotech/20/05/16140357/the-week-ahead-in-biotech-asco-menlo-and-merck-fda-decisions-ipos-in-the-spotlight <p>Biotech stocks could not sustain the uptrend in the holiday-shortened week, even as traders digested COVID-19-related news flow, clinical readouts, ASCO presentations and a few FDA approvals.</p> <p><strong>Arca Biopharma Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abio#NASDAQ">ABIO</a>) was the best performing biotech stock of the week, as it rallied in reaction to an <a href="https://www.benzinga.com/general/biotech/20/05/16128864/arca-biopharma-rallies-200-on-covid-19-plans">announcement</a> from the company regarding testing of its pipeline asset for COVID-19-associated coagulopathy.</p> <p>The week also saw <strong>Merck &amp; Co., Inc. </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mrk#NYSE">MRK</a>) taking a giant leap of faith into the <a href="https://www.benzinga.com/general/biotech/20/05/16106601/why-shares-of-womens-health-focused-biopharma-evofem-are-rallying">COVID fray</a> after remaining non-committal thus long.</p> <p>Here are the key catalysts for the unfolding week.</p> <h3>Conferences</h3> <p>Jefferies Virtual Healthcare Conference: June 2-4<br /> European Academy of Allergy and Clinical Immunology, or EAACI, Digital Conference 2020: June 6-8</p> <h3>PDUFA Dates</h3> <p>The FDA is set to rule on <strong>Menlo Therapeutics Inc&#39;s </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnlo#NASDAQ">MNLO</a>) FMX103 - 1.5% minocycline foam -, which came into its stable via its Foamix acquisition, as a ...</p><p><a href=https://www.benzinga.com/general/biotech/20/05/16140357/the-week-ahead-in-biotech-asco-menlo-and-merck-fda-decisions-ipos-in-the-spotlight alt=The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight>Full story available on Benzinga.com</a></p> ABBV ABIO ASCO AYLA AZN Biotech BMY CLDX Earnings IBB MNLO MRK NBIX News Penny Stocks PLX REPL XBI Health Care FDA IPOs Top Stories Trading Ideas General PLX US74365A1016 XBI US78464A8707 ABIO US00211Y1001 CLDX US15117B1035 IBB US4642875565 NBIX US64125C1099 AZN US0463531089 BMY US1101221083 MRK US58933Y1055 REPL ABBV MNLO AYLA News Earnings Biotech Penny Stocks Health Care FDA IPOs Top Stories Trading Ideas General Benzinga Sat, 30 May 2020 13:25:31 +0000 Shanthi Rexaline 16140357 at https://www.benzinga.com Mondelēz International Participates in JDE Peet's IPO; Retains Significant Stake https://www.benzinga.com/pressreleases/20/05/g16136936/mondel-z-international-participates-in-jde-peets-ipo-retains-significant-stake <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <ul> <li>Mondelēz International contributed to JDE Peet&#039;s successful listing on Euronext Amsterdam</li> <li>Company will retain two board seats at the global coffee and tea company on listing</li> </ul> <p>CHICAGO, May 29, 2020 (GLOBE NEWSWIRE) -- Mondelēz International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ" rel="nofollow">MDLZ</a>) today announced its participation in JDE Peet&#039;s admission to listing and trading of its ordinary shares on Euronext Amsterdam (Euronext Amsterdam: JDEP) and confirmed that it will be selling a portion of its stake in the coffee and tea company as part of the secondary component of JDE Peet&#039;s offering. The offer price was set at €31.50 per share.</p> <p>After settlement and depending on exercise of the over-allotment option, Mondelēz International&#039;s stake in JDE Peet&#039;s will be between 22.9 percent and 23.4 percent. Mondelēz International will retain two seats on the board of JDE Peet&#039;s, which has a portfolio of ...</p><p><a href=https://www.benzinga.com/pressreleases/20/05/g16136936/mondel-z-international-participates-in-jde-peets-ipo-retains-significant-stake alt=Mondelēz International Participates in JDE Peet&#039;s IPO; Retains Significant Stake>Full story available on Benzinga.com</a></p> KDP MDLZ News IPOs Markets Press Releases Fri, 29 May 2020 12:06:03 +0000 Globe Newswire 16136936 at https://www.benzinga.com